Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10291288 | 0.93 | L3MBTL1 (0.65) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL12424223 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL673399 | 0.83 | — | — | |
| SCHEMBL19169445 | 0.80 | ATM (0.42) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL11240 | 0.80 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL7599563 | 0.79 | L3MBTL1 (0.88) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8418308 | 0.79 | BLM (0.43) | L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL18896657 | 0.79 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL293140 | 0.78 | L3MBTL1 (0.60) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL18896656 | 0.78 | L3MBTL1 (0.65) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | L3MBTL1 3149/4885MEN1 4070/4885KMT2A 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.